HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Mazaitis, J. K. Articles by Reba, R. C. Search for Related Content PubMed PubMed Citation Articles by Mazaitis, J. K. Articles by Reba, R. C.

Radioiodinated Estrogen Derivatives

George Washington University, Washington, D.C.
Central Research Laboratory, Sankyo Co., Ltd., Tokyo, Japan

Correspondence: For reprints contact: J. Krijn Mazaitis, Radiopharmaceutical Chemistry Sect., George Washington Univ., 2300 Eye St., N.W., Washington, DC 20037.

ABSTRACT

Monoiodohexestrol exhibits 10 to 15% specific binding to the 8S estrogen receptor while the remainder binds to nonreceptor 4S proteins. Reduction of nonreceptor binding with either thyroxine or 8-anilino-1-naphthalene sulfonic acid was not quantitative. Thus no accurate determination of the concentration of receptor sites in the radioreceptor assay was possible by graphical analysis.

Two additional estrogens—17-[¹²⁵I]iodoethynylestradiol and 17-[¹²⁵I]iodoethynyl-11ß-methoxy estradiol—were synthesized at high specific activity. Although the iodoethynyl derivatives were stable under synthetic conditions, deiodination in the presence of proteins is too fast to allow either in vivo or in vitro use.

To make these compounds clinically useful, therefore, chemical modification to reduce nonreceptor binding and the rate of dehalogenation must be undertaken.